Comparing different therapeutic classes for the treatment of osteoarthritis of the knee: data from the OMERACT-OARSI responder criteria analysis  by Band, Philip A.
Letter to the Editor
Comparing different therapeutic classes for the treatment of
osteoarthritis of the knee: data from the OMERACT-OARSI
responder criteria analysis
OsteoArthritis and Cartilage (2005) 13, 449
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2005.02.001
International
Cartilage
Repair
SocietyThe recently reported responder criteria for osteoarthritis
(OA) clinical trials [1] analyze data for three different
therapeutic classes in knee OA: Non-steroidal anti-inﬂam-
matory drugs (NSAIDs), systemic speciﬁc OA agents and
intra-articular speciﬁc OA agents. Though the objective of
the analysis was not to compare therapeutic classes, and
direct comparison between the therapeutic classes is
limited by differences in trial design, patient population
and the lack of randomization, an aspect of the data
relevant to patient care is worth additional comment. This
aspect of the data is timely considering recent concerns
regarding the cardiovascular risks associated with some
cox-selective NSAIDs [2], and the known gastrointestinal
side effects of non-selective NSAIDs [3].
When comparing treatments for knee OA administered by
oral vs intra-articular routes using the Outcome Measures in
Rheumatology e Osteoarthritis Research Society Interna-
tional (OMERACT-OARSI) responder criteria, the effective-
ness of the intra-articular route is consistently as good or
better than the oral route. This was noted in the original
OARSI report [4] and is true for both the elaboration and
revisit databases, regardless of the responder deﬁnition
used. Using Proposition A as an example (Table II in
reference 1), the percent responders to the ‘‘active’’ intra-
articular group was 92% using the elaboration database
and 58% using the revisit database. This compared to 52%
and 59% NSAID responders in the elaboration and revisit
databases, respectively, and 51% and 31% responders to
knee OA systemic speciﬁc drugs. The magnitude of the
treatment effect for intra-articular agents was also as good
or better than for the orally administered therapeutic
classes. Though the differences between the elaboration
and revisit databases highlight the limitation of comparisons
across heterogeneous studies, the intra-articular agents
had a consistently high percent of responders, and
a consistently high treatment effect, in all scenarios
evaluated.
Local therapy can ﬁll an important gap in the treatment
paradigm for knee OA. NSAIDs prescribed for knee OA
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York, NY 10016, USA; E-mail: bandp01@med.nyu.edu44have limited effectiveness and can have signiﬁcant iatro-
genic toxicity. Comorbidities, drug interactions and the need
for long term administration, all common in the knee OA
population, exacerbate the potential for NSAID-related side
effects. Local treatment with intra-articular agents offers
a valuable option for patients in whom one or two painful
joints drive their disability. Researchers developing new
treatments for OA should consider these factors.
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